KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Capital Expenditures: 2017-2025

Historic Capital Expenditures for Elanco Animal Health (ELAN) over the last 8 years, with Sep 2025 value amounting to $92.0 million.

  • Elanco Animal Health's Capital Expenditures rose 119.05% to $92.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.0 million, marking a year-over-year increase of 85.11%. This contributed to the annual value of $147.0 million for FY2024, which is 5.00% up from last year.
  • Latest data reveals that Elanco Animal Health reported Capital Expenditures of $92.0 million as of Q3 2025, which was up 61.40% from $57.0 million recorded in Q2 2025.
  • Elanco Animal Health's 5-year Capital Expenditures high stood at $99.0 million for Q4 2021, and its period low was $17.0 million during Q2 2021.
  • Moreover, its 3-year median value for Capital Expenditures was $42.0 million (2024), whereas its average is $45.5 million.
  • Over the last 5 years, Elanco Animal Health's Capital Expenditures had its largest YoY gain of 253.57% in 2021, and its largest YoY loss of 71.59% in 2021.
  • Elanco Animal Health's Capital Expenditures (Quarterly) stood at $99.0 million in 2021, then decreased by 22.22% to $77.0 million in 2022, then crashed by 46.75% to $41.0 million in 2023, then increased by 14.63% to $47.0 million in 2024, then soared by 119.05% to $92.0 million in 2025.
  • Its Capital Expenditures stands at $92.0 million for Q3 2025, versus $57.0 million for Q2 2025 and $65.0 million for Q1 2025.